Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice.

Debra L Richardson Julia Coelho França Quintanilha Natalie Danziger Gerald Li Ethan S Sokol Alexa B Schrock Ericka M Ebot Neeru Bhardwaj Tanesha Norris Anosheh Afghahi Anthony Frachioni Christina R Washington Lauren Dockery Julia A Elvin Ryon P Graf Kathleen M Moore

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

HRDsig predicted benefit of mPARPi better than BRCAalt. HRDsig(+) patients had favorable outcomes, even among BRCAwt patients, while HRDsig(-) patients showed no enrichment for benefit with mPARPi. HRDsig might predict benefit from mPARPi regardless of BRCAalt status.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
healthcare
prognostic factors
systematic review
randomized controlled trial
primary care
type diabetes
dna damage
oxidative stress
metabolic syndrome
patient reported outcomes
quality improvement